Albert Eisenbarth | Clinical Trials | Best Scholar Award

Published on by Top Pharmaceutical

Dr. Albert Eisenbarth | Clinical Trials | Best Scholar Award

Entomologe at Bundeswehr Hospital Hamburg | Germany

Dr. Albert Eisenbarth is a biologist specializing in parasitology, vector biology, and emerging infectious diseases. He earned his doctorate at the University of Tübingen, focusing on Onchocerca ochengi and its relevance to river blindness epidemiology. His career spans international research assignments across Africa, Asia, and Europe, contributing to studies on vector-borne diseases, zoonotic pathogens, and host-parasite interactions. Dr. Eisenbarth has worked at prestigious institutions including the Friedrich Loeffler Institute for Animal Health and the University of Tübingen. With over a decade of field and laboratory expertise, his work bridges veterinary medicine, parasitology, and global health, advancing infectious disease control strategies.

Publication Profile 

Scopus

Education 

Dr. Albert Eisenbarth completed his MSc in Parasitology at the Institute of Tropical Medicine, University of Tübingen, where he conducted his thesis on anisakid nematodes in Australian waters. He pursued doctoral studies at the University of Tübingen, earning his Doctor of Biology degree with a thesis on the biology of Onchocerca ochengi and its epidemiological implications for river blindness. His academic training also included international research exchanges at the University of Melbourne, the Royal Melbourne Institute of Technology, the University of Cape Town, and Kasetsart University in Bangkok. His education combines parasitology, vector biology, and tropical infectious disease research.

Experience 

Dr. Albert Eisenbarth has held diverse research and professional roles. He served as a Research Fellow at the Friedrich Loeffler Institute for Animal Health, working on novel and emerging infectious diseases. Previously, he completed his doctoral and postdoctoral research at the University of Tübingen and in Cameroon within the Onchocerciasis Programme. His career includes positions as Clinical Data Manager at Kendle GmbH and scientific assistant roles at the University of Tübingen. He has undertaken extensive international assignments in Mozambique, Mauritania, Cameroon, Thailand, France, Australia, and South Africa. His expertise encompasses parasitology, vector ecology, epidemiology, and zoonotic disease transmission at the human-animal interface.

Awards and Honors 

Dr. Albert Eisenbarth has received multiple awards and grants for his scientific contributions. He co-coordinated major DFG-funded projects investigating zoonotic viral transmission, including Rift Valley Fever and Crimean-Congo Hemorrhagic Fever in Africa. As principal investigator, he secured a RiSC Young Scientist grant for research on genetic susceptibility to tick-borne diseases in African cattle. His international collaborations earned him a South East Asia–European Union NET II Fellowship, supporting One Health research. He has also been recognized with travel grants from the German Society for Parasitology and the Erwin Riesch Foundation. Additionally, he was awarded DAAD fellowships for both MSc and doctoral studies.

Research Focus 

Dr. Albert Eisenbarth research focuses on parasitology, vector-borne diseases, and zoonotic infections affecting both human and animal health. He has conducted extensive work on the epidemiology of Onchocerca volvulus and Onchocerca ochengi, contributing to onchocerciasis control strategies. His studies include the diversity, abundance, and pathogen carriage of hematophagous vectors such as mosquitoes and ticks in Africa. Additionally, he investigates emerging viral diseases, including Rift Valley Fever and Crimean-Congo Hemorrhagic Fever, across the livestock-wildlife-human interface. Through molecular and field-based approaches, his work integrates parasitology, virology, and epidemiology, providing valuable insights for global health, One Health initiatives, and disease elimination programs.

Publication Top Notes

Molecular detection of Leishmania (Sauroleishmania) adleri (Trypanosomatida: Trypanosomatidae) in Sergentomyia sp. sand flies (Diptera: Psychodidae) in Mali and Niger

Mosquito survey in Mauritania: Detection of Rift Valley fever virus and dengue virus and the determination of feeding patterns

Conclusion

Dr. Albert Eisenbarth possesses the academic excellence, research productivity, and global health relevance that make him a strong candidate for the Research for Best Scholar Award. His innovative studies on parasitic and vector-borne diseases, coupled with his ability to secure competitive grants and engage in international collaborations, demonstrate outstanding scholarly merit. With continued expansion into broader leadership and translational activities, he is well-positioned to further influence the fields of parasitology, epidemiology, and infectious disease research. His track record aligns with the award’s goal of recognizing impactful and forward-looking scientific scholarship.

Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Director at nd Xiangya Hospital | Central South University | China

Prof. Dr. Dongshan Zhang is a highly respected Chief Physician and Professor at Central South University, China. A postdoctoral fellow trained in the United States, he is a PhD supervisor and a recipient of China’s National Top Talent Program for Science and Technology Leaders. As Director of both the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair, he leads cutting-edge medical research. With over 46 SCI publications and multiple patents, his work in acute kidney injury has earned him prestigious awards and international acclaim.

Publication Profile 

Education 

Prof. Zhang pursued rigorous academic training in China and completed his postdoctoral fellowship in the United States, gaining advanced insights into nephrology and translational medicine. He earned his medical and doctoral degrees from top Chinese medical universities, where he laid the foundation for his expertise in acute organ injury. His exposure to international research environments shaped his multidisciplinary approach. Now, as a PhD supervisor, he mentors future scientists and clinicians, promoting global research collaborations and innovation in clinical nephrology and emergency medicine.

Experience 

Prof. Zhang currently serves as Chief Physician and Professor at Central South University, where he is also a Distinguished Shenghua Scholar Professor. He directs two major research institutes: the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair in Hunan Province. Over his career, he has led four NSFC-funded national research projects and served as Associate Editor for top journals. His commercialized patents and extensive publication record reflect his commitment to translational research and clinical excellence.

Awards 

Prof. Zhang’s outstanding contributions have earned him the First Prize of the Natural Science Award of Hunan Province. He has been recognized as a National Top Talent in Science and Technology, awarded for his pioneering work in nephrology and acute organ injury. His research papers have graced the covers of leading journals, affirming his global impact. As a Distinguished Shenghua Scholar Professor and active editorial board member, he continues to shape scientific thought and innovation. His accolades highlight both clinical expertise and trailblazing research excellence.

Research Focus 

Prof. Zhang’s primary research centers on Acute Kidney Injury (AKI), encompassing mechanisms of injury, repair, and translational approaches to therapy. His work explores inflammation, apoptosis, and molecular pathways involved in kidney damage. He leads interdisciplinary teams to develop innovative drug targets and biomarkers, bridging basic science and clinical application. With support from multiple NSFC grants, his lab integrates in vivo models, molecular profiling, and AI-driven analytics to advance precision nephrology. His research contributes to improving prognosis and treatment in critical care settings.

Publication Top Notes

Title: PRDM16 acts as a homeostasis regulation factor to suppress the transition of AKI to CKD via upregulation of eukaryotic initiation factor 6
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: PRDM16 suppresses pyroptosis to attenuate the progression of AKI caused by rhabdomyolysis via upregulation of USP10
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: Mmu_circ_0005698/hsa_circ_0085381/miR-532-3p/Arhgdib axis mediates the ischemic progression of acute kidney injury
Journal: International Immunopharmacology
Year: 2025

Title: Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial
Journal: Nature Medicine
Year: 2025

Title: Inhibition of Mettl3 alleviates low-dose cisplatin-induced renal fibrosis and enhances the chemotherapeutic efficacy in mouse models of cancer
Journal: International Journal of Biological Sciences
Year: 2025

Title: PRDM16 suppresses ferroptosis to protect against sepsis-associated acute kidney injury by targeting the NRF2/GPX4 axis
Journal: Redox Biology
Year: 2024

Title: NRF1-induced mmu_circ_0001388/hsa_circ_0029470 confers ferroptosis resistance in ischemic acute kidney injury via the miR-193b-3p/TCF4/GPX4 axis
Journal: Life Sciences
Year: 2024

Title: Discovery and verification of mmu_Circ_26986/hsa_Circ_0072463 as a potential biomarker and intervention target for sepsis-associated acute kidney injury
Journal: Not specified
Year: Not specified

Conclusion

Prof. Dr. Dongshan Zhang is an outstanding candidate for the Research for Best Researcher Award, possessing an exceptional track record in acute organ injury research, prolific publication output, successful grant leadership, and tangible innovations through patents. His blend of academic excellence, clinical relevance, and translational success makes him a model researcher with substantial contributions to global health and kidney disease research. With minor expansion in global collaborations and strategic outreach, his impact can become even more internationally transformative.

Premal Thaker | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Premal Thaker | Clinical Trials | Best Researcher Award

Dr. Premal Thaker at Washington University School of Medicine, United States.

Dr. Premal Thaker is a renowned gynecologic oncologist and professor at Washington University, St. Louis. With a medical degree from Allegheny University and advanced training at MD Anderson Cancer Center, she has led impactful clinical research in ovarian and endometrial cancers 🧪. As Director of Gynecologic Oncology Clinical Research and Division Chief (2025–present), her leadership is pivotal in advancing cancer therapies. A respected speaker, grant recipient, and editorial board member 📚, Dr. Thaker has earned numerous accolades including “Best Doctors in America” and “Castle Connolly Top Doctor” 🏅. Her dedication to women’s health continues to inspire globally.

Publication Profile 

Scopus

Education

Dr. Premal Thaker’s illustrious academic journey began with a BA in Biology from Villanova University 🎓, followed by an MD from Allegheny University and an MS in Cancer Biology from the University of Texas 🧬. She completed specialized training in gynecologic oncology at MD Anderson Cancer Center and recently attended a leadership course at Harvard 🏛️. Dr. Thaker has held esteemed positions at Washington University, advancing from Assistant Professor to Division Chief of Gynecologic Oncology 👩‍⚕️. A distinguished researcher and educator, she is also the David and Lynn Mutch Distinguished Professor and Director of Clinical Research.

Awards

Dr. Premal Thaker has received numerous accolades throughout her distinguished career in gynecologic oncology 🎖️. Beginning with academic honors such as the Dean’s List and Alpha Epsilon Delta Honor Society in the early 1990s 📚, she went on to earn prestigious awards for scientific presentations and publications, including the J.G. Moore Award 🧪 and GCF/Eli Lilly Fellow Award 🧬. Recognized as one of the Best Doctors in St. Louis (2013–2025) and America (2020–2024) 👩‍⚕️, she was also named a Castle Connolly Top Doctor and Fellow of AGOS. In 2025, she joined Avant-Garde Health’s Research All-Stars.

Research Focus 

Dr. Premal Thaker’s research primarily centers on gynecologic oncology, with a strong focus on ovarian and endometrial cancers 🧫. Her work explores immune checkpoint inhibitors, personalized gene therapy, molecular profiling, and health disparities in clinical trial enrollment, particularly in Hispanic and Asian populations 🌍. She also investigates novel immunotherapy combinations, real-world treatment outcomes, and genomic biomarkers for therapy response and survival 🧪. Her multidisciplinary efforts contribute to precision medicine and the advancement of targeted therapies for women’s reproductive cancers, driving impactful, patient-centered innovations in oncology care.

Publication Top Notes

  • Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel
  • OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer
  • Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
  • Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study
  • Diverse case series of granulomatous peritonitis mimicking advanced ovarian cancer
  • Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study
  • Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis
  • Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer
  • Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma
  • Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study

Mert Zeytinoğlu | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Mert Zeytinoğlu | Clinical Trials | Best Researcher Award

Assoc. Prof. Dr. Mert Zeytinoğlu, Ege University Faculty of Dentistry Department of Oral and Maxillofacial Surgery, Turkey

Assoc. Prof. Dr. Mert Zeytinoğlu is a distinguished academic at Ege University, Faculty of Dentistry, specializing in Oral and Maxillofacial Surgery. With a Ph.D. from Ege University (2004), his research spans oral surgery, clinical sciences, and dental implantology. He has authored over 40 publications, holds an H-index of 3, and has led numerous projects on piezosurgery, wound healing, and dental stem cells. Known for his contributions to surgical techniques and cardiovascular safety in dental anesthesia, Dr. Zeytinoğlu actively mentors postgraduate theses and advances innovative practices in dental science.

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Mert Zeytinoğlu began his academic journey at Ege University, where he earned his Bachelor’s degree in Dentistry from the Faculty of Dentistry between 1993 and 1998. His dedication to clinical sciences led him to pursue a Ph.D. in the same institution, specializing in the Department of Clinical Sciences, which he successfully completed between 1999 and 2004. 🇹🇷 Throughout his education, he demonstrated a strong commitment to advancing dental knowledge and practice in Turkey. Dr. Zeytinoğlu’s academic foundation reflects his deep passion for oral health and clinical excellence.

Experience

Assoc. Prof. Dr. Mert Zeytinoğlu has built a distinguished academic career at Ege University’s Faculty of Dentistry. Since 2015, he has been serving as an Associate Professor in the Department of Clinical Sciences, contributing significantly to academic development and clinical training. 🏫 Earlier, from 1999 to 2004, he worked as a Specialist Doctor in the Division of Clinical Sciences, specifically in the Department of Oral and Maxillofacial Surgery, where he gained extensive hands-on experience in complex dental surgeries. 🦷🔬 His academic and clinical roles reflect a deep commitment to excellence in dental education and patient care.

Awards

Assoc. Prof. Dr. Mert Zeytinoğlu received a prestigious award in 2015 for his outstanding research titled “Süt dişi- mesiodens ve daimi molar dişlerin kök hücrelerinin immünohistokimyasal ve histokimyasal yöntemlerle belirlenmesi” (Determination of Stem Cells in Primary, Mesiodens, and Permanent Molar Teeth Using Immunohistochemical and Histochemical Methods). 🧬🦷 His project earned Second Place in the Project Competition of Occupational Organizations during the İzmir Chamber of Dentists Scientific Congress and Exhibition. 🎖️ This recognition highlights his innovative approach to dental research and his contributions to scientific advancement in stem cell applications within oral health.

Research Focus

Assoc. Prof. Dr. Mert Zeytinoğlu primarily focuses on Oral and Maxillofacial Surgery 🦷 and Dental Radiology, with special expertise in the diagnosis and surgical management of jaw pathologies, including cysts, tumors, and bone defects. His research includes the use of fractal analysis 📈, peri-implant bone assessment, and management of impacted third molars, as well as multidisciplinary approaches to benign jaw tumors and dental anomalies. He also investigates the cardiovascular effects of dental anesthetics ❤️, showing interest in dental care for medically compromised patients. His work bridges clinical surgery with diagnostic innovation and patient-centered dental care.

Publication Top Notes

Oral mucosal ulceration: a manifestation of previously undiagnosed pulmonary tuberculosis

Fractal analysis for the assessment of trabecular peri-implant alveolar bone using panoramic radiographs

Effect of tube drainage compared with conventional suturing on postoperative discomfort after extraction of impacted mandibular third molars

Treatment of nonsyndromic dentigerous cysts in primary dentition

Multidisciplinary Management of Benign Jaw Tumors in

Comparison of 2 different flap techniques in the surgical removal of bilateral impacted mandibular third molars

Holter ECG assessment of the effects of three different local anesthetic solutions on cardiovascular system in the sedated dental patients with coronary artery disease/Üç …

Myofibroma of the gingiva: report of a case

Assist Prof Dr. AYŞEGÜL KILIÇLI|Clinical Trials| Best Researcher Award

Published on by Top Pharmaceutical

Assist Prof Dr. AYŞEGÜL KILIÇLI|Clinical Trials |Best Researcher Award|

Assist Prof Dr. AYŞEGÜL KILIÇLI at mus alparslan university, Turkeys

PROFILE  

scopus

Orcid

 

Early Academic Pursuits 🎓

Assist. Prof. Dr. Ayşegül KILIÇLI embarked on her academic journey with a profound dedication to the field of nursing, focusing specifically on obstetrics and gynecology. She earned her Bachelor’s degree in Nursing from a reputable institution, where her commitment to the healthcare field began to shine. Driven by a desire to enhance her expertise and contribute significantly to her field, she pursued a Master’s degree in Obstetric and Gynecology Nursing. This was followed by rigorous research and a doctoral degree (Ph.D.) in the same domain, equipping her with advanced knowledge and research skills essential for a successful academic and professional career.

Professional Endeavors 👩‍⚕️

Dr. KILIÇLI is currently serving as an Assistant Professor in the Obstetric and Gynecology Nursing Department at Muş Alparslan University Health Sciences Faculty. Her role involves teaching, mentoring, and guiding students through their academic and clinical experiences. Her professional journey reflects a commitment to advancing nursing education and practice. She is actively involved in several research projects and has published extensively in high-impact journals. Her work focuses on improving healthcare practices and patient outcomes, particularly in the field of obstetrics and gynecology.

Contributions and Research Focus 🔬

Dr. KILIÇLI’s research is primarily concentrated on obstetric and gynecology nursing. One of her notable completed research projects is a randomized controlled trial examining the effect of neurolinguistic programming and progressive muscle relaxation exercises on breastfeeding success and self-efficacy. This innovative study has been instrumental in advancing knowledge about non-pharmacological interventions in maternal care. Her research contributions are reflected in her publications in SCI-E journals, where her work is highly regarded by the scientific community.

Accolades and Recognition 🏆

Dr. KILIÇLI’s research excellence and contributions to the field have earned her recognition in various forums. Her work has been cited in prestigious databases, including Science Citation Index-Expanded (SCI-E), Scopus, and Web of Science (ESCI). She is celebrated for her significant contributions to advancing obstetric and gynecology nursing practices. Her role as a corresponding researcher further highlights her leadership and expertise in the field, establishing her as a respected figure in the global research community.

Impact and Influence 🌍

Dr. KILIÇLI’s impact extends beyond her research and academic contributions. Her work has positively influenced clinical practices, particularly in improving breastfeeding outcomes and maternal self-efficacy. By integrating innovative approaches into her research, she has contributed to the development of more effective strategies in nursing care. Her influence is also evident in the academic and professional growth of her students, who benefit from her extensive knowledge and mentorship.

Legacy and Future Contributions 🔮

As a pioneering researcher in obstetric and gynecology nursing, Dr. KILIÇLI is poised to leave a lasting legacy in her field. Her dedication to advancing maternal and child health through research and education is commendable. Looking ahead, Dr. KILIÇLI plans to continue her research with a focus on exploring new interventions and improving existing practices. Her future contributions are expected to further enhance nursing care practices and patient outcomes, reinforcing her position as a leading expert in her field.

🎓Publication 

The effect of neurolinguistic programming and progressive muscle relaxation exercises on breastfeeding success and breastfeeding self-efficacy: A randomized controlled trial

  • Authors   :Kiliçli, A., Gül, S.
  • Journal    :Explore
  • Year         :2024

Effect of Reflexology on Pain, Fatigue, Sleep Quality, and Lactation in Postpartum Primiparous Women After Cesarean Delivery: A Randomized Controlled Trial

Stress, Anxiety, and Postpartum Depression in Parents with Premature Infants in Neonatal Intensive Care Unit

Stigmatizing attitudes, beliefs, and actions of women towards abortion in rural regions with high fertility

Women’s reproductive behaviour and perspectives on fertility, and their modifying factors, in a Turkish province with a high fertility rate